Publication | Open Access

Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation

Hematological MalignancyTransplantationMarrow TransplantationImmunologyHematologyAml PatientsOutcome PredictorMedicineCell TransplantationMinimal Residual DiseaseMyeloid Neoplasia